麦嘉怡 1陈嘉瑶 2李晓珠 2黄红兵 1刘韬 1周捷1
作者信息
- 1. 中山大学肿瘤防治中心药学部,华南恶性肿瘤防治全国重点实验室,广东省鼻咽癌诊治研究重点实验室(广东 广州 510060)
- 2. 广州新华学院药学院(广东 广州 510520)
- 折叠
摘要
Abstract
Objective To evaluate the efficacy of different anaplastic lymphoma kinase(ALK)inhibitors combined with anlotinib in the treatment of non-small cell lung cancer(NSCLC).Methods Clinical data of drug resistant NSCLC patients with ALK positive mutation was collected who were treated with ALK inhibitors and anlotinib synchronously.According to different regimens,three groups were set,alectinib+anlotinib,ceritinib+anlotinib,and crizotinib+anlotinib.The latest imageological examination results of the patient before the synchronous therapy was set as the baseline to evaluate the therapeutic effect according to Recist1.1.The event free survival(EFS)of each group was calculated with disease progression,patient death,treatment discontinuation and changing regimen as endpoints.Data of tumor markers,hematology test,liver function,cardiac function,renal function biochemical examination was collected and analyzed statistically before and after the combination therapy,with P＜0.05 as the statistically significant difference.Results After screening,clinical data of 49 patients were collected.Twenty-three patients in the alectinib+anlotinib group,with a disease control rate(DCR)of 86.96%;mean EFS was(10.8±3.6)months,median EFS of 8.3 months;14 patients in the ceritinib+anlotinib group,with a DCR of 71.43%,mean EFS was(6.5±2.9)months,median EFS was 5.6 months;12 patients in the crizotinib+anlotinib group,with a DCR of 66.67%,mean EFS was(7.7±3.2)months,median EFS was 7.2 months.EFS of alectinib+anlotinib group was longer significantly than the other two groups(P＜0.05).Only CyFra21-1,increased significantly after the combination of crizotinib and anlotinib(P＜0.05).No statistically significant difference in biochemical test and hematology test before and after the treatment(P＞0.05).Conclusions The therapeutic effect of ALK inhibitors with anlotinib was ordered,alectinib being the most effective,followed by ceritinib and finally crizotinib.The combination of ALK inhibitors with anlotinib did not cause any abnormal results in the examination of heart,liver,kidney and blood cells.关键词
间变性淋巴瘤激酶/阿来替尼/塞瑞替尼/克唑替尼/安罗替尼Key words
anaplastic lymphoma kinase/alectinib/ceritinib/crizotinib/anlotinib
